Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13

29 Jun 2017

Abstract excerpt

Widespread resistance to first-line TB drugs is a major problem that will likely only be resolved through the development of new drugs with novel mechanisms of action. We have used structure-guided methods to develop a lead molecule that targets the thioesterase activity of polyketide synthase Pks13, an essential enzyme that forms mycolic acids, required for the cell wall of Mycobacterium tuberculosis. Our lead,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biochemical and Molecular Research
Share to Cancer therapeutics and mechanisms
Share to Microbial Natural Products and Biosynthesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28669536
DOI: 10.1016/j.cell.2017.06.025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13PMID 28669536Read ↗

Direct inhibitors of InhA with efficacy similar or superior to isoniazid in novel drug regimens for tuberculosisSemantic proximity Read ↗

Screening of Compounds for Anti-tuberculosis Activity, and in vitro and in vivo Evaluation of Potential CandidatesSemantic proximity Read ↗

Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis.Semantic proximity Read ↗

The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosisSemantic proximity Read ↗

Mycobacterial Membrane Protein Large 3 (MmpL3) Inhibitors: A Promising Approach to Combat TuberculosisSemantic proximity Read ↗

Side Chain-modified Benzothiazinone Derivatives with Anti-Mycobacterial ActivitySemantic proximity Read ↗

Thienopyrimidine amide analogs target MmpL3 in Mycobacterium tuberculosis.Semantic proximity Read ↗

Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3.Semantic proximity Read ↗

Can We Exploit Inflammasomes for Host-Directed Therapy in the Fight against Mycobacterium tuberculosis Infection?Semantic proximity Read ↗

New and Old Hot Drug Targets in TuberculosisSemantic proximity Read ↗

NSC19723, a Thiacetazone-Like Benzaldehyde Thiosemicarbazone Improves the Efficacy of TB Drugs In Vitro and In VivoSemantic proximity Read ↗

Pre-clinical evaluation of quinoxaline-derived chalcones in tuberculosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.